Scholarlink

In recent years, precision medicine, through the careful consideration of individual genomic profiles, biomarkers, lifestyles, and environmental differences, has gained significant attention due to its potential for tailoring diagnosis, treatment, and prevention strategies for patients with interstitial lung disease (ILD). A crucial aspect of this approach is recognizing the impact of patient race and ethnicity on ILD incidence and subtype, associated risk factors, prognosis, and healthcare access, in a way to personalize patient care. However, race and ethnicity are complex societal concepts that are subject to varying interpretations and are often underutilized and misused in the medical literature, which can perpetuate racial healthcare disparities by concealing fundamental determinants of health or promoting erroneous associations. Racial and ethnic minorities experience numerous barriers to health care resulting in reduced access to and quality of care. Furthermore, race matters beyond socioeconomic determinants when considering respiratory health disparities, as these determinants are not equivalent across different racial groups. Addressing these inequalities is essential for reducing ILD burden, particularly in low-resource settings, as neighborhood disadvantage is a powerful predictor of outcomes in fibrotic ILD. Environmental and occupational exposure occurs disproportionately in minorities, may it be through air pollution or hazardous occupations. These findings are of great concern, because air pollution has been linked to subclinical ILD as well as increased mortality in IPF patients. Additionally, genetic susceptibility in racial and ethnic groups may, in part, be attributed to genetic variations between these populations, as well as the influence of environmental and demographic factors that are unique to these groups on genetic predisposition. Ultimately, high-quality racial and ethnic data are needed, as the inclusion of minorities in clinical trials remains poor, impeding our understanding of the differences in ILD presentation and outcome.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Influence of Race and Ethnicity on the Precision Diagnosis and Treatment of ILD

  • 章节

  • 发表日期：

    2025年

查看全文
  • Vincent Ferraro,
  • Julie Morisset

摘要

In recent years, precision medicine, through the careful consideration of individual genomic profiles, biomarkers, lifestyles, and environmental differences, has gained significant attention due to its potential for tailoring diagnosis, treatment, and prevention strategies for patients with interstitial lung disease (ILD). A crucial aspect of this approach is recognizing the impact of patient race and ethnicity on ILD incidence and subtype, associated risk factors, prognosis, and healthcare access, in a way to personalize patient care. However, race and ethnicity are complex societal concepts that are subject to varying interpretations and are often underutilized and misused in the medical literature, which can perpetuate racial healthcare disparities by concealing fundamental determinants of health or promoting erroneous associations. Racial and ethnic minorities experience numerous barriers to health care resulting in reduced access to and quality of care. Furthermore, race matters beyond socioeconomic determinants when considering respiratory health disparities, as these determinants are not equivalent across different racial groups. Addressing these inequalities is essential for reducing ILD burden, particularly in low-resource settings, as neighborhood disadvantage is a powerful predictor of outcomes in fibrotic ILD. Environmental and occupational exposure occurs disproportionately in minorities, may it be through air pollution or hazardous occupations. These findings are of great concern, because air pollution has been linked to subclinical ILD as well as increased mortality in IPF patients. Additionally, genetic susceptibility in racial and ethnic groups may, in part, be attributed to genetic variations between these populations, as well as the influence of environmental and demographic factors that are unique to these groups on genetic predisposition. Ultimately, high-quality racial and ethnic data are needed, as the inclusion of minorities in clinical trials remains poor, impeding our understanding of the differences in ILD presentation and outcome.